Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel
LON:GSK

GSK Q3 Earnings Report

GSK logo
GBX 1,765.50 +6.50 (+0.37%)
As of 12:04 PM Eastern
ProfileEarnings HistoryForecast

GSK EPS Results

Actual EPS
GBX 55
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

GSK Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

GSK Announcement Details

Quarter
Q3
Date
10/29/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

GSK Earnings Headlines

GSK-owned ViiV succeeds in late-stage trial for HIV therapy
 |  msn.comhttps://www.msn.com/en-us/news/other/gsk-owned-viiv-succeeds-in-late-stage-trial-for-hiv-therapy/ar-AA2dGq55
GSK Updates Market on Total Voting Rights and Share Capital
October 1, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/gsk-updates-market-on-total-voting-rights-and-share-capital-8?utm_source=marketbeat.com&utm_medium=referral
First Look: Elon’s “Starphone”
Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.tc pixel
October 6 at 1:00 AM  |  Stansberry Research (Ad)
Deutsche Bank Aktiengesellschaft Reaffirms Hold Rating for GSK (LON:GSK)
October 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31071950
Wave Life Sciences Ltd.: Wave Life Sciences Announces GSK's Selection of siRNA program to Transition to GSK for Further Development
September 30, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69718314-wave-life-sciences-ltd-wave-life-sciences-announces-gsk-s-selection-of-sirna-program-to-transition-to-gsk-for-further-development-399.htm
Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development
September 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/wave-life-sciences-announces-gsk-113000645.html
See More GSK Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GSK? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GSK and other key companies, straight to your email.

About GSK

GSK (LON:GSK), together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development, as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

View GSK Profile
Earnings Tools